Immune cells may hold the key to Parkinson's origins

NCT ID NCT07026929

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study explores whether the immune system plays a role in starting and driving Parkinson's disease. Researchers will collect blood, spinal fluid, stool, and saliva from people with REM sleep behavior disorder (a strong early sign of Parkinson's), people already diagnosed with Parkinson's, and healthy volunteers. They will look for immune cells that mistakenly attack a protein called alpha-synuclein, which is linked to Parkinson's, and check whether gut microbes might trigger this immune response. The goal is to understand how Parkinson's begins and progresses, which could lead to earlier detection or new prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could reveal early immune triggers of Parkinson's disease, pointing toward new ways to detect or prevent it before motor symptoms appear.
What could go wrong
This is an observational study, not a treatment trial. It may not prove cause and effect, and findings might not translate into clinical tools or therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC REM BEHAVIOR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.